King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price
Executive Summary
King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business
You may also be interested in...
Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say
Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field
Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say
Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain